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Misfolding, aggregation and deposition of α-synuclein (α-syn) are major pathologic
characteristics of Parkinson’s disease (PD) and the related synucleinopathy, multiple
system atrophy (MSA). The spread of α-syn pathology across brain regions is thought
to play a key role in the onset and progression of clinical phenotypes. Thus, there is
increasing interest in developing strategies that target and attenuate α-syn aggregation
and spread. Recent studies of brain-penetrating polyphenolic acids, namely, 3hydroxybenzoic acid (3-HBA), 3,4-dihydroxybenzoic acid (3,4-diHBA), and 3-(3hydroxyphenyl)propionic acid (3-HPPA) that are derived from gut microbiota metabolism
of dietary polyphenols, show in vitro ability to effectively modulate α-syn misfolding,
oligomerization, and mediate aggregated α-syn neurotoxicity. Here we investigate
whether 3-HBA, 4-hydroxybenzoic acid (4-HBA), 3,4-diHBA, or 3-HPPA interfere with
α-syn spreading in a cell-based system. Using HEK293 cells overexpressing α-synA53T-CFP/YFP, we assessed α-syn seeding activity using Fluorescence Resonance
Energy Transfer (FRET) to detect and quantify α-syn aggregation. We demonstrated
that 3-HPPA, 3,4-diHBA, 3-HBA, and 4-HBA significantly attenuated intracellular α-syn
seeding aggregation. To determine whether our compounds could inhibit brain-derived
seeding activity, we utilized insoluble α-syn extracted from post-mortem MSA or
PD brain specimens. We found that 3-HPPA effectively attenuated MSA-induced
aggregation of monomer into high molecular weight aggregates capable of inducing
intracellular aggregation. Outcomes from our studies suggest interactions between gut
microbiome and certain dietary factors may form the basis for effective therapies that
modulate pathologic α-syn propagation. Collectively, our findings provide the basis for
future developments of probiotic, prebiotic, or synbiotic approaches for modulating the
onset and/or progression of α-synucleinopathies.
Keywords: α-synuclein, aggregation, microbiome, polyphenol, Parkinson’s disease, multiple system atrophy

INTRODUCTION
Parkinson’s disease (PD) and multiple system atrophy (MSA) involve abnormal aggregation of
the protein α-synuclein (α-syn) (Papp et al., 1989; Spillantini et al., 1998a,b). The progression
of α-syn pathology in neuronal cell bodies Lewy bodies (LBs) or Lewy neurites (LNs) in these
neurodegenerative conditions is thought to involve transcellular spread of aggregation-prone forms
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of α-syn, throughout the neuraxis (Frost and Diamond, 2010;
Guo and Lee, 2014). Some studies hypothesize initiation of
α-syn misfolding in peripheral sites such as the olfactory bulb
or enteric plexus of the gastrointestinal tract that subsequently
propagates to the brain (Hawkes et al., 2007; Shannon et al.,
2012). Animal models of gut-injected α-syn recombinant fibrils
result in spread of α-syn pathology to the brain over time
and vagotomy potentially modulates future development of
PD-related symptoms and pathology (Svensson et al., 2015;
Uemura et al., 2018; Kim et al., 2019). α-syn pathology has
been found in sites as remote as the submandibular gland and
peripheral nerves of the skin and colonic submucosa (Beach et al.,
2010; Shannon et al., 2012; Adler et al., 2014, 2016; Donadio
et al., 2014), implying that accumulation of pathologic forms
of α-syn is not solely a central nervous system based process.
Given potential cell-to-cell propagation of aggregation-prone
forms, there is increasing interest in developing interventional
strategies that will attenuate α-syn spread through interference
with abnormal aggregation.
There is also evidence that α-syn may assemble into
different fibrillar forms and that distinct conformations inherent
to misfolded forms of α-syn may underlie different clinical
presentations seen, especially in regard to the synucleinopathies,
PD and MSA (Bousset et al., 2013; Peelaerts et al., 2015; Prusiner
et al., 2015; Woerman et al., 2015; Peng et al., 2018; Yamasaki
et al., 2019). The existence of different conformations of the
α-syn aggregated state becomes important especially in light of
therapies targeting α-syn aggregation.
Emerging evidence suggests that gut microbiota dysbiosis
is a risk factor for developing α-syn pathology. A number of
studies have documented the presence of dysbiosis in patients
with PD suggesting that this is a risk factor for development
of PD (Keshavarzian et al., 2015; Scheperjans et al., 2015;
Heintz-Buschart et al., 2018). Moreover, recent preclinical
observations support a cause-and-effect relationship between gut
microbiota dysbiosis and PD pathophysiology (Erny et al., 2015;
Klingelhoefer and Reichmann, 2015; Sampson et al., 2016). In
particular in mice with neuronal overexpression of a wild-type
human α-syn protein, colonization with fecal microbiota from
PD patients significantly promoted PD-type pathophysiology
while colonization via healthy donor fecal microbiota did not
develop a similar phenotype (Sampson et al., 2016). Moreover,
there is evidence suggesting that gut microbiota contribute to
PD pathology by disrupting interactions between the enteric
nervous system and the brain (Klingelhoefer and Reichmann,
2015). Recently, it has been reported that functional bacterial
amyloid proteins may promote cross-seeded aggregation of
α-syn, amyloid β-protein, tau, and others to initiate prionlike propagation (Friedland et al., 2020). On the other hand,
gut microbiota may contribute to PD pathophysiology by
metabolizing dietary compounds such as dietary fibers into shortchain fatty acids that are essential in promoting brain microglia
maturation, leading to a heightened neuroinflammatory response
which may contribute to PD pathophysiology (Sampson et al.,
2016). Phenolic compounds modulate the gut-brain axis, which
transform these phenolic compounds into physiologically
active and neuroprotective compounds through the gut
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microbiome-metabolism (Reddy et al., 2020). These metabolites
may exert their neuroprotective effects in neurodegenerative
diseases such as PD and Alzheimer’s disease (AD) (Reddy et al.,
2020). We recently observed that interpersonal heterogeneity
in gut microbiota may lead to interpersonal variabilities the
efficacy to metabolize dietary flavanols into select biologically
available phenolic acid metabolities (Ho et al., 2019). Preclinical
investigation by our group has demonstrated that dietary
supplementation with select bioactive polyphenol-rich dietary
preparations, such as a select grape seed polyphenol extract
(GSPE) and a standardized Bioactive Dietary Polyphenol
Preparation (BDPP, comprised of a select Concord grape
juice, GSPE and resveratrol) are mechanistically effective in
modulating diverse neuropathologic phenotypes (Frolinger et al.,
2019). Following GSPE supplementation, we observed brain
accumulations of select polyphenol metabolites in the form of
monophenolic acids, such as 3-hydroxybenzoic acid (3-HBA)
and 3-(3-hydroxyphenyl)propionic acid (3-HPPA), that are
generated by gut microbiota fermentation of GSPE. Furthermore,
previous work by our group has demonstrated treatment with a
flavanol rich preparation (FRP) in gnotobiotic mice yields brain
bioavailable polyphenol metabolites including the monophenolic
compounds, 4-HBA, 3,4-dihydroxybenzoic acid (3,4-diHBA),
and 3-HPPA (Pasinetti et al., 2018). We demonstrated that
three of the 15 biologically available FRP-derived metabolites
identified in cecum specimens of gnotobiotic mice, namely
3,4-diHBA, 3-HBA, and 3-HPPA, accumulate in the brain
although 12 phenolic acid metabolites were detectable in plasma
specimens from the mice (Ho et al., 2019). We found that these
three brain-available phenolic acids are bioactive in modulating
α-syn misfolding in vitro. Moreover, we also demonstrated that
bioactive phenolic acids effectively modulate the development to
PD-type neuropathy and behavioral phenotypes in a drosophila
model of α-synucleinopathy (Ho et al., 2019).

METHODS
Reagents
3-HBA, 4-HBA, 3,4-diHBA, and 3-HPPA (Ho et al., 2019;
Supplementary Figure S1) were obtained commercially from
Sigma-Aldrich (United States). Monomeric synthetic α-syn was
purchased from rPeptide (Watkinsville, GA, United States).

Human Brain Specimens
The Movement Disorders Center Neuropathology Core,
Washington University, St. Louis, provided clinically and
neuro-pathologically well-characterized postmortem frozen
brain tissue (Table 1; Cairns et al., 2015). Post mortem brains
were collected from 50% male/female subjects at ages ranging
from 59 to 86 years of age. Routinely, microscopy was performed
on the left hemibrain and biochemistry was performed using the
right hemibrain. α-syn-immunoreactive inclusion bodies were
observed only in PD and MSA utilizing phosphor-dependent
anti-α-syn immunohistochemistry (Cell Applications, San
Diego, CA, United States) and #64 (Wako, Osaka, Japan). Frozen
tissue was prepared as previously described (Bagchi et al., 2013).
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TABLE 1 | Clinical and neuropathological characteristics of brain samples for α-synucleinopathy.
Sample
diagnosis

Seeding
activity

Sample area

Disease
duration
(years)

Post mortem
interval (h)

Primary
diagnosis

Additional
diagnoses

BraaK LB
stage (0–6)

Braak NFT
stage (I-VI)

Amyloid stage
(A–C)

Low

AC

17

5

DLBD

ADNC,
TDP-MTL

6

III

C

PD 2

Low

AC

22

4

DLBD

ADNC

6

I

C

PD 5

High

AC

12

13

DLBD

0

5

I

0

MSA 1

Low

BG CB

13

16

MSA*

ADNC

0

II

B

MSA 4

High

BG

8

5

MSA*

ADNC

0

I

A

PD 1

PD, Parkinson’s disease; MSA, mutiple system atrophy; AC, anterior cingulate; BG, basal ganglia; CB, cerebellum; DLBD, diffuse lewy body disease; *, MSA-nigrostriatal
type; ADNC, Alzheimer disease neuropathologic change; TDP-MTL, TDP-43 proteinopathy in medial temporal lobe.

Tissue was first dissected into small pieces (˜1 mm square) using
a scalpel and a cutting board cooled with solid CO2 . Tissue
was then weighed and serially extracted with a series of buffers,
using a dounce homogenizer (Kontes) for homogenization.
A ratio of 3 mL buffer to 1 g of tissue was maintained throughout
the extraction process. Initial homogenization was performed
in high salt buffer (50 mM Tris-HCl, pH 7.4, 750 mM NaCl,
5 mM EDTA) with protease inhibitors (Sigma), followed by
centrifugation at 100,000 × g for 20 min at 4◦ C. Supernatant
was removed and used as the buffer “soluble” fraction. The pellet
was homogenized in 1% Triton X-100 in high salt buffer with
protease inhibitors, followed by centrifugation at 100,000 × g
for 20 min at 4◦ C. The pellet was extracted with 1M sucrose
and 1% Triton X-100 in high salt buffer. The myelin component
and supernatant were removed, and the pellet was then washed
twice with Tris-buffered saline (TBS), resuspended in TBS, with
protease inhibitor (Sigma), aliquoted, and frozen at –80◦ C and
used as the detergent “insoluble” fraction.

monomeric concentration. This was done in the presence of
Lipofectamine reagent (Invitrogen, Waltham, MA, United States)
in reaction volumes of 20 µl/reaction. Samples were then added
dropwise to wells (total volume per well 150 µl). Technical
quadruplicates were performed for each sample. Unless otherwise
specified, incubation with cells was for 24–72 h, depending on
the experiment. All experiments involving brain lysate were
incubated for 24 h. Cells were then trypsinized and transferred
to 96-well round-bottom plates, fixed in 4% paraformaldehyde
(Electron Microscopy Services, Hatfield, PA) in PBS for 10
min, then centrifuged and resuspended in flow buffer (1
mM EDTA and 1% FBS in HBSS). Cell aggregate load was
quantified using a MACSQuant VYB (Miltenyi, Auburn, CA,
United States) as previously described (Holmes et al., 2014).
Analysis was performed using FlowJo v10 software (TreeStar,
Ashland, OR, United States).

α-Syn Aggregation

All analyses, unless otherwise noted, were performed using
Prism software (Graphpad). Student t-tests were performed with
post hoc Dunnett corrections for the number of comparisons
per set. p-values of < 0.05 were considered to be statistically
significant. Graphs are displayed as mean ± SEM.

Statistics

Recombinant α-syn was resusupended in aggregation buffer (100
mM NaCl, 20 mM TrisHCl, pH 7.4) to generate a 446 µM
stock. This was further diluted in aggregation buffer to final
concentration of 10 µM in final volume of 200 µl. Aggregation
in the presence or absence of phenolic acid compounds at a
molar ratio of 10:1 phenolic acid compound: α-syn monomer
concentration was used. For experiments utilizing human brain,
5 µL of insoluble fraction, sonicated for 3 min at 65 A on a
Qsonica 700 (Newtown, CT, United States) at 4◦ C, was added to
each reaction mixture, for a final volume of 200 µl per reaction
mixture. Aggregation was initiated by shaking at 1,500 rpm at
37◦ C for 24 h in an Eppendorf Thermomixer C (Hauppauge,
NY, United States).

RESULTS
Gut Microbiome-Modified Phenolic Acid
Compounds Interfere With Formation of
Aggregation-Prone Forms of
Recombinant α-Syn
Based on the efficacy of 3-HBA, 3,4-diHBA and 3-HPPA to
interfere with aggregation in prior studies, we extended our
current investigation into a cell-based model of α-syn aggregation
and tested the ability of gut microbiota derived phenolic
compounds to interfere with α-syn aggregation derived from
α-syn derived from PD and MSA brain fractions.
To determine whether the compounds 3-HBA, 4-HBA,
3,4-diHBA, and 3-HPPA interfere with aggregation of α-syn
monomer, we incubated 10 µM recombinant α-syn monomer
with phenolic compounds utilizing a paradigm of constant
shaking at physiologic temperatures for 24 h which, in prior

Fluorescence Resonance Energy
Transfer (FRET Assay)
Monoclonal biosensor cells (stable cell line 1H α-syn A53TCFP/YFP) made as previously described (Yamasaki et al., 2019)
were plated in 96-well plates at 20,000 cells per well and
grown overnight. Aggregated α-syn formed in the presence
or absence of phenolic compounds was introduced into
the cells at various concentrations (i.e., 2, 10, 350 nM, as
specified in experiments below) as calculated from the initial
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FIGURE 1 | Phenolic acids inhibit formation of aggregation-prone forms of α-syn. α-syn-A53T-CFP/YFP cells were assessed for% positive FRET signal after a 24 h
incubation with varying concentrations of α-syn aggregated in the presence of phenolic acid compounds (A) 3-HPPA (B) 3,4-diHBA (C) 3-HBA and (D) 4-HBA.
FRET signal was quantified in a second set of α-syn-A53T-CFP/YFP cells after a 72 h incubation in the presence of varying concentrations of α-syn exposed to (E)
3-HPPA (F) 3,4 diHBA (G) 3-HBA and (H) 4-HBA during the aggregation phase. Data from each subject is presented as a Mean ± SEM from four replicate assays.
Experimental replicates were 1–2 (*p < 0.05, **p < 0.01, Unpaired t-test compared to α-syn aggregated without exposure to phenolic acid).
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cyclic amplification assays, such as real-time quaking-induced
conversion and protein misfolding cyclic amplification have
successfully utilized this method in combination with thioflavin
T (ThT) for detection of α-syn prone aggregating forms
in CSF and brain tissue of patients with synucleinopathies
(Herva et al., 2014; Fairfoul et al., 2016; Shahnawaz et al.,
2017).
To determine whether polyphenolic compounds would have
the ability to inhibit α-syn seeding activity as generated by
forms found in PD and MSA brain, we incubated polyphenolic
compounds with insoluble brain fractions (generated by serial
buffer and detergent extraction) in a similar monomeric shaking
paradigm. We utilized brain samples with neuropathologicallyconfirmed diagnoses of PD or MSA. Insoluble fractions of
these brains could be classified as either “low seeders” or “high
seeders” given prior assessment via FRET (Yamasaki et al., 2019).
Reaction mixture was exposed to biosensor cells in the presence
of lipofectamine and aggregate load was quantified at 24 h.
There was no significant inhibition of formation of aggregate
generating forms from “high seeder” type brain insoluble extracts
from PD and MSA (Table 2). However, it is possible that
“high seeder” brain fractions may contain a more aggregateprone form of α-syn than “low seeder” counterparts, and
thus outstrip the ability of phenolic compounds to inhibit
aggregate formation. We therefore evaluated “low seeder” forms
to see if phenolic compounds could have inhibitory activity
on aggregate formation generated by these neuropathologicallycharacterized brain fractions. Strikingly, both 3,4-diHBA and
3-HPPA significantly inhibited generation of aggregate-prone
forms for both MSA and PD “low seeder” samples (Table 2).
A subsequent expansion of this testing to a limited number of
“low seeder” brains also showed the ability to inhibit aggregate
formation in both PD and MSA although the sample of PD2 (AC
area) and MSA1 (CB area) showed inconsistency (Table 2).

experiments, resulted in robust fibril formation (Ono et al.,
2012). We then applied varying concentrations of aggregate
mixture with α-syn concentration ranging from 2 to 666 nM
to α-syn -A53T-CFP/YFP cells and incubated for a 24 and 72
h period. Phenolic acid inhibition of the α-syn aggregation was
then quantified with flow cytometry via measurement of FRET
signal (% positive cells, which is indicative of the formation and
accumulation of intracellular α-syn aggregates).
We observed that phenolic compounds 3-HPPA, 3,4-diHBA
3-HBA, and 4-HBA inhibited the formation of α-syn species
capable of seeding aggregation of α-syn within biosensor cells at
1:10 ratio. This was most apparent at an early (24 h) timepoint of
incubation in the cell-based assay (Figures 1A–D). Compound
3-HPPA inhibited generation of α-syn intracellular aggregate
formation over a range of seeded concentrations (2, 70, and
350 nM) (Figure 1A). 3-HBA and 4-HBA similarly showed
inhibitory activity against α-syn aggregation, especially at higher
concentrations of α-syn (70 and 350 nM) at the 24 h timepoint
(Figures 1C,D). 3,4-diHBA was less effective at suppressing the
generation of α-syn seed competent forms (Figure 1B).
The generation of intracellular aggregates was also quantified
by FRET at the 72 h timepoint to determine if increased
incubation time resulted in change in aggregate formation.
Compound 3-HPPA had persistent reduction of aggregation
at this timepoint at a high (350 nM) α-syn concentration
(Figure 1E). Compound 3,4-di-HBA did demonstrate significant
inhibition of aggregation-prone α-syn forms at the 2 and 350 nM
concentrations at the 72 h timepoint only (Figure 1F), Other
samples tested, 3-HBA and 4-HBA, did not have significant
impact on FRET seeding activity, although a slight elevation in
aggregation was seen at the 70 nM seeded concentration only
(Figures 1G,H).

α-Syn Aggregation Induced by Brain
Samples Is Inhibited by Specific
Gut-Modified Phenolic Compounds

DISCUSSION

Recombinant α-syn fibrils generated from monomer by a
high-speed shaking paradigms may not necessarily have
physiologic relevance to forms generated in the brain during
conditions of slow progressive neurodegeneration seen in
PD and the related synucleinopathy, MSA. However, new

Recent studies support the idea that abnormal proteins are
amplified by the same mechanism as prions and are transmitted
between cells in major neurodegenerative diseases, including
PD and AD (Frost and Diamond, 2010; Guo and Lee, 2014).

TABLE 2 | Phenolic acids inhibit formation of α-syn aggregates induced by exposure to PD and MSA brain extracts with low potency for seed formation.
Phenotype

Brain region

MSA 4

BG

PD 5

AC

300 nM α-syn

Control 300 nM

3-HPPA 3 µM

3,4-diHBA 3 µM

High seeders (% FRET positive cells)
36.6 ± 1.6

36.1 ± 0.7

37.8 ± 1.4

35.5 ± 1.1

16.0 ± 0.8

37.3 ± 1.6

36.6 ± 1.7

Low seeders (% FRET positive cells)
PD 1

AC

21.8 ± 0.5

14.2 ± 0.5**

11.4 ± 0.5**

PD 2

AC

32.6 ± 0.9

31.1 ± 1.7

32.9 ± 2.1

MSA 1

BG

MSA 1

CB

27.0 ± 1.0

24.4 ± 1.0

16.3 ± 0.7**

16.1 ± 0.4**

22.7 ± 0.8

32.1 ± 1.6

34.6 ± 1.3

PD, Parkinson’s disease; MSA, multiple system atrophy; AC, anterior cingulate; BG, basal ganglia; CB, cerebellum. Each sample contains one individual with four technical
replicates ± SEM. **p < 0.01, by one-way ANOVA with post-hoc Dunnett test compared to the brain extracts without exposure to phenolic acid.
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FIGURE 2 | Inhibitory effects of 3-HPPA, 3,4-diHBA, 3-HBA, and 4-HBA on intracellular α-syn fibril formation. In the cell, monomer of α-syn may aggregate to form
intermediate aggregates such as oligomers, HMW aggregates and finally fibrils as Lewy body. On the other hand, fibrillar seeds of α-syn entering from outside the
cell exert as seeds to form α-syn fibrils within the cell. 3-HPPA may prevent not only penetration of fibrillar seeds of α-syn into cells but also aggregation and seeding
pathways of α-syn. 3,4-di-HBA may mainly prevent aggregation and seeding pathways of α-syn.

In this study 3-HPPA and 3,4-diHBA, and to a lesser extent
3-HBA and 4-HBA demonstrated the ability to partially inhibit
generation of aggregate prone forms from α-syn monomer.
Compounds 3-HPPA, 3-HBA and 4-HBA all showed a robust
level of inhibition of α-syn seeding activity across multiple seeded
concentrations of the reaction mixture. This was detected at an
early incubation timepoint. Only 3-HPPA showed consistency
across multiple timepoints. The loss of effectiveness of 3-HBA
and 4-HBA, and even slight loss of signal in 3-HPPA at the
72 h timepoint could be due to several factors. There is an
overall reduction in % positive cells detected by FRET at most
of the different α-syn concentrations at 72 h, implying that
biosensor cells without aggregates continued to propagate, while
cells with aggregates did not efficiently pass the aggregates on
to their daughter cells. Another explanation is that there was
decreased viability of cells with inclusions by the 72 h timepoint.
A final possible explanation is the difference of the inhibitory
effect of these compounds on penetration of fibrillar seeds into
cells. Considering aggregate data for the 24 and 72 h, 3-HPPA
may prevent not only penetration of fibrillar seeds of α-syn into
cells but also interfere with aggregation and seeding pathways of
α-syn, whereas 3,4-di-HBA may mainly prevent aggregation and
seeding pathways of α-syn (Figure 2).

Experimental evidence for this cell-to-cell transmission of
pathological α-syn also includes the results of transplantation
of embryonic dopaminergic neurons into PD patients (Li
et al., 2008; Li et al., 2016). These reports highlighted the
possibility that misfolded α-syn accumulated in PD patients was
transmitted from the host brain cells to the grafts, resulting
in the appearance of Lewy pathologies in the transplanted
cells. Seed-dependent aggregation of α-syn is also observed in
various kinds of cultured cells and primary-cultured neurons
(Desplats et al., 2009; Luk et al., 2009). Introduction of
synthetic α-syn fibrils into human neuroblastoma SH-SY5Y
cells expressing α-syn induced intracellular accumulation of
phosphorylated α-syn, which is similar to abnormal α-syn
deposits in the brains of patients with LB diseases (Nonaka
et al., 2010). Furthermore, these α-syn aggregates bound
thioflavin dye, which means β-sheet structure. Immunoelectron microscopy revealed that Sarkosyl-insoluble fractions
extracted from SH-SY5Y cells into which fibrils had been
introduced contained abundant fibrillar structures labeled with
an antibody specific for α-syn phosphorylated at Ser129
(Nonaka et al., 2010). Thus, nucleation and prion-like seedtemplated amplification of abnormal α-syn aggregates are
reproduced in vitro.
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FIGURE 3 | Aggregate morphology within α-syn CFP/YFP cells exposed to brain insoluble fractions. Cells exposed to α-syn fibrils develop intracellular aggregates
which differ in morphology from aggregates formed by exposure to insoluble brain extract from PD and MSA brain. (A) Control CFP/YFP cells only (no exogenous
α-syn) (B) Cells exposed to 10 nM preformed α-syn fibrils (C,D) PD and MSA insoluble brain fractions utilized in “high seeder” experiments form aggregates with
diverse morphology when exposed to α-syn CFP/YFP cells (E–H) PD and MSA insoluble brain fractions utilized in “low seeder” experiments did not demonstrate
robust aggregate formation when introduced into α-syn CFP/YFP cells. These images were adapted from our previous paper (Yamasaki et al., 2019). Scale bars
indicate 10 µm.

potential than physiologically-derived α-syn aggregation-prone
types and thus may be less inhibited by phenolic compounds.
To enhance physiologic relevance, we tested the ability of
phenolic compounds to inhibit the generation of aggregateprone forms of α-syn from a limited number of PD and MSA
brain extracts. Both 3,4-di-HBA and 3-HPPA demonstrated the
ability to inhibit seeding activity from PD and MSA brain. The
inconsistency of seeding inhibition by phenolic acids for “high
seeder” and “low seeder” MSA and PD brain could be related to
the affinity of the proteopathic form of α-syn to form aggregates.
There is some indication that different synucleinopathies may
harbor different forms or “strains” of α-syn (Bousset et al., 2013;
Guo et al., 2013; Watts et al., 2014; Peelaerts et al., 2015; Peng
et al., 2018; Candelise et al., 2019; Yamasaki et al., 2019). It is
possible that “low seeder” vs. “high seeder” PD and MSA brains
contain diverse strains with varied propensity for aggregate
formation and that phenolic acid inhibition of aggregation relies
on the underlying conformation of the proteopathic α-syn form
(Figure 3). Ongoing studies are investigating specific forms of
aggregated α-syn that are generated by incubation of α-syn
alone, or by incubation in the presence of MSA and PD
brain extracts. Nonetheless, our observation suggests that select
brain-accumulating phenolic acids derived from gut microbiota
metabolism of dietary polyphenols may interfere with α-syn
spreading by attenuating the generation of oligomeric α-syn
forms capable of inducing further misfolded α-syn. Recent
Cryo-electron microscopy analysis has shown that the fibril

In previous work, we demonstrated that 3-HPPA, 3,4diHBA, and 3-HBA are capable of attenuating the assembly
of monomeric synthetic α-syn into fibrils as detected by ThT
signal (Ho et al., 2019). Interestingly, with the cell-based
method of α-syn aggregation used in these experiments, we
observed that only 3-HPPA, 3-HBA, and 4-HBA were able
to provide some level of attenuation of the assembly the
synthetic α-syn into forms capable of supporting the induction
of intracellular α-syn aggregation. Phenolic acid 3,4-diHBA
was less consistent in this respect. These contrasting results
could be due to differences in assay detection substrate. ThT
will detect a fibrillar β-pleated sheet formation, which is
thought to be a late-stage form in the process of aggregation
of amyloid proteins (Ono et al., 2008; Soto and Pritzkow,
2018). Small oligomeric (non-fibrillar) forms are also efficient
in inducing aggregation of monomeric α-syn (Ono et al.,
2011; Chen et al., 2015). While the ThT assay therefore, is
useful for detecting the end-product of aggregation, smaller
forms with potency for aggregation may be more sensitively
detected by cell-based assays or other methods that specifically
target oligomers.
One explanation for some inconsistency with seeding
response may be due to the potency of fibril formation as initiated
by a high-speed shaking paradigm. Although this is a popular
paradigm for creation of pre-formed fibrils, formation of these
aggregated forms does not mimic physiologic conditions. The
species formed may have different conformations or aggregation
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structure of α-syn differs in vitro and in vivo (Meade et al.,
2019). Furthermore, it has been pointed out that the fibril
structure may be different depending on the post-translational
modification (Meade et al., 2019). Further structural studies
are essential not only to determine whether α-syn expressing
in monoclonal biosensor cell has a sensory modification, but
also to reveal the structural destabilization of intracellular
α-syn aggregates by phenoloic compounds. Outcomes from
our studies suggest interactions between gut microbiome and
certain dietary factors may form the basis for effective therapies
that modulate pathologic α-syn propagation. Collectively, our
findings provide the basis for future development of probiotic,
prebiotic, or symbiotic approaches for modulating the onset
and/or progression of PD, MSA and other synucleinopathies.
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